AETERNA ZENTARIS (NASDAQ:AEZS)
0.82
-0 (-0%)
| AETERNA ZENTARIS (NASDAQ:AEZS) Delayed : | |||||
|---|---|---|---|---|---|
| Previous Close | $0.82 | 52 Week High | $3.25 | ||
| Open | $0.82 | 52 Week Low | $0.60 | ||
| Day High | $0.83 | P/E | N/A | ||
| Day Low | $0.81 | EPS | $0.00 | ||
| Volume | 70,900 | ||||
| More AEZS Info: Chart SEC Filings Profile Historical Options | |||||
What is this?Friends, Peers and Foes
| Ticker | # Stories | Ticker | # Stories |
|---|---|---|---|
| KERX | 18 | AEZ | 12 |
| SNY | 3 | ACAS | 2 |
| JAZZ | 2 | IXYS | 2 |
| AGCO | 2 | AIM | 2 |
| ASCE | 2 | PGI | 2 |
| ALTH | 2 | ATCO | 2 |
Entities who have mentioned AEZS
- StreetInsider.com Morning Movers | View Related Stories »
- Soleil Securities | View Related Stories »
- Unusual 11 Mid-Day Movers | View Related Stories »
- Cowen & Co | View Related Stories »
- Deutsche Bank | View Related Stories »
- Barclays | View Related Stories »
- Highland Capital | View Related Stories »
- Northland Securities | View Related Stories »
- Notable Mergers and Acquisitions | View Related Stories »
- JMP Securities | View Related Stories »
- Canaccord Adams | View Related Stories »
- Robert W Baird | View Related Stories »
- Trading Radar | View Related Stories »
View All Major News StreetInsider.com Major News for AEZS
- Aeterna Zentaris (AEZS) Posts Q3 Loss of 19c, Beats by 2c
- AEterna (AEZS) Signs Development Deal With Sanofi-Aventis Worth $165M Or More
View All ReportsStreetInsider.com Reports on AEZS
- AEterna Zentaris (AEZS) Terminates Cetrorelix Collaboration with Sanofi-Aventis (SNY)
- AEterna Zentaris (AEZ) and Keryx BioPharma (KERX) Initiate KRX-0401 Phase 3
- Unusual 11 Mid-Day Movers 12/07: ROY, IHO, ASIA, ZILG Higher; SOMX, ZLC, AEZS, NCT Lower
- Morning Movers 12/07: IHO, ZILG, ASIA, NVDA, MDR Higher; SOMX, AEZS, ZLC, BTH, ALTH, HEB Lower
- AEterna Zentaris (AEZ) Updates on Phase 3 of Z-036 in BPH
View All Press ReleasesCompany Press Releases on AEZS
- Æterna Zentaris Partner Keryx Announces Special Protocol Assessment Agreement with FDA for Phase 3 Trial of Perifosine (KRX-0401) in the Treatment of Patients with Refractory Metastatic Colorectal Ca
- Æterna Zentaris Partner Keryx Announces Positive Phase 2 Results for Perifosine as a Single Agent for the Treatment of Advanced Waldenstrom's Macroglobulinemia
- Keryx Biopharmaceuticals Announces Positive Phase 2 Study Results of Perifosine as a Single Agent for the Treatment of Advanced Waldenstrom's Macroglobulinemia
- Keryx Biopharmaceuticals, Inc. to Conduct Conference Call to Discuss KRX-0401 (Perifosine) Clinical Development Program in Colorectal Cancer
- Liberty Analytics Co. Initiates Independent Research Coverage on AEterna Zentaris Inc.
StreetInsider Reports on AEZS by Category
View All BlogsBlogs on AEZS
- AstraZeneca to Ax 8,000 More Workers: Biotech's Latest Mishaps
- The Complete List of Canadian Stocks Traded on the Nasdaq
- This Week's Failed Trials, Missed Targets in Biotech
- 13 Biotechs to Watch for at Hematology Conference
- Analyst upgrades, downgrades and initiations: AXP, CHL, FLOW, GLW, GS ...
Comments on AEZS
No comments are currently available.
